79 related articles for article (PubMed ID: 38622479)
1. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis.
Hu Y; Chen J; Lin K; Yu X
Front Endocrinol (Lausanne); 2023; 14():1160936. PubMed ID: 37288301
[TBL] [Abstract][Full Text] [Related]
2. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of Thyroid-stimulating immunoglobulin in Recent Onset Symptomatic Thyroid Eye Disease.
Lai KKH; Aljufairi FMAA; Sebastian JU; Wei Y; Jia R; Chan KKW; Au EYL; Lee ACH; Ng CM; Yuen HKL; Yip WWK; Young AL; Cheng GPM; Tham CCY; Pang CP; Chong KKL
Eur Thyroid J; 2024 Jun; ():. PubMed ID: 38847819
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate for the treatment of thyroid eye disease.
Strianese D; Iuliano A; Ferrara M; Comune C; Baronissi I; Napolitano P; D'Alessandro A; Grassi P; Bonavolontà G; Bonavolontà P; Sinisi A; Tranfa F
J Ophthalmol; 2014; 2014():128903. PubMed ID: 24678411
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
Tamhankar MA; Pradeep T; Chen Y; Briceño CA
J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
[TBL] [Abstract][Full Text] [Related]
6. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.
Lee C; Park JW; Kim YD; Woo KI
Int Ophthalmol; 2024 Apr; 44(1):179. PubMed ID: 38622479
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
12. Echographic Assessment of Extraocular Muscle Response to Teprotumumab.
Tran C; Pham CM; Simmons BA; Warner LL; Fuhrmeister LJ; Shriver EM
Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):336-339. PubMed ID: 34652310
[TBL] [Abstract][Full Text] [Related]
13. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
14. Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.
Naselli A; Moretti D; Regalbuto C; Arpi ML; Lo Giudice F; Frasca F; Belfiore A; Le Moli R
Front Endocrinol (Lausanne); 2020; 11():609895. PubMed ID: 33414766
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]